MAGE3-AS02B
Open study
Study to be open
Closed study
16032
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma
Back to Protocol section